Skip to content
10-Q

Quarterly Report

BENITEC BIOPHARMA INC. BNTC

0001193125-25-283274

← back to feed
Filed
Nov 14, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Nov 14, 2025 33.86M sh
Shares Diluted Q1 2026 · Sep 30, 2025 41.52M sh
Shares Diluted restated Q1 2026 · Sep 30, 2024 27.88M sh
Operating Cash Flow Q1 2026 · Sep 30, 2025 −$3.35M
Operating Cash Flow Q1 2026 · Sep 30, 2024 −$4.59M
Cash And Equivalents Q1 2026 · Sep 30, 2025 $94.48M
Cash And Equivalents Q1 2026 · Jun 30, 2025 $97.74M
Stockholders Equity Q1 2026 · Sep 30, 2025 $93.6M
Stockholders Equity Q1 2026 · Jun 30, 2025 $97.3M
Stockholders Equity Q1 2026 · Sep 30, 2024 $64.18M
Stockholders Equity Q1 2026 · Jun 30, 2024 $47.25M
Current Liabilities Q1 2026 · Sep 30, 2025 $2.03M
Current Liabilities Q1 2026 · Jun 30, 2025 $1.8M
Total Liabilities Q1 2026 · Sep 30, 2025 $2.43M
Total Liabilities Q1 2026 · Jun 30, 2025 $2.3M
Current Assets Q1 2026 · Sep 30, 2025 $95.08M
Current Assets Q1 2026 · Jun 30, 2025 $98.52M
Total Assets Q1 2026 · Sep 30, 2025 $96.03M
Total Assets Q1 2026 · Jun 30, 2025 $99.59M
Eps Diluted Q1 2026 · Sep 30, 2025 −$0.22
Eps Diluted restated Q1 2026 · Sep 30, 2024 −$0.18
Eps Basic Q1 2026 · Sep 30, 2025 −$0.22
Eps Basic restated Q1 2026 · Sep 30, 2024 −$0.18
Sga Expense Q1 2026 · Sep 30, 2025 $6.43M
Sga Expense Q1 2026 · Sep 30, 2024 $2.21M
Rd Expense Q1 2026 · Sep 30, 2025 $3.37M
Rd Expense Q1 2026 · Sep 30, 2024 $3.59M
Net Income Q1 2026 · Sep 30, 2025 −$8.97M
Net Income Q1 2026 · Sep 30, 2024 −$5.06M
Operating Income Q1 2026 · Sep 30, 2025 −$9.8M
Operating Income Q1 2026 · Sep 30, 2024 −$5.79M
Revenue Q1 2026 · Sep 30, 2025 $0
Revenue Q1 2026 · Sep 30, 2024 $0